New imaging technique for pancreatic cancer treatment response
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
This study is testing a new imaging method to help doctors see pancreatic cancer better and understand how well different treatments might work for patients, so they can tailor the best care for each person.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10927190 on NIH RePORTER |
What this research studies
This research focuses on developing a novel imaging technique using CCR2 PET to better visualize pancreatic cancer and predict how well patients will respond to standard therapies and new CCR2-targeted treatments. By understanding the tumor microenvironment and the role of specific immune cells, the research aims to enhance treatment effectiveness. Patients will be monitored through advanced imaging to assess the presence of CCR2, which is linked to tumor growth and treatment resistance. The goal is to create a diagnostic tool that can guide personalized treatment strategies for pancreatic cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) who are undergoing treatment.
Not a fit: Patients with other types of cancer or those who are not diagnosed with PDAC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment plans for patients with pancreatic cancer, improving their chances of recovery.
How similar studies have performed: Previous research has shown promising results in targeting the CCR2 pathway in preclinical models, indicating potential for success in clinical applications.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Dehdashti, Farrokh — Washington University
- Study coordinator: Dehdashti, Farrokh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.